NN Investment Partners Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

NN Investment Partners Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.79M	Buy	+10,948	New	+$1.67M	0.01%	552
2021 Q4	–	Sell	-31,296	Closed	-$5.91M	–	785
2021 Q3	$5.91M	Buy	31,296 +5,470	+21%	+$1.03M	0.03%	384
2021 Q2	$4.38M	Buy	25,826 +6,362	+33%	+$932K	0.02%	429
2021 Q1	$2.75M	Buy	19,464 +2,851	+17%	+$429K	0.02%	500
2020 Q4	$2.16M	Buy	16,613 +4,099	+33%	+$547K	0.01%	507
2020 Q3	$1.82M	Sell	12,514 -164	-1%	-$23.3K	0.01%	502
2020 Q2	$1.88M	Buy	+12,678	New	+$1.71M	0.01%	508
2019 Q2	–	Sell	-13,266	Closed	-$1.24M	–	745
2019 Q1	$1.24M	Buy	+13,266	New	+$1.11M	0.01%	567
2017 Q3	–	Sell	-5,858	Closed	-$467K	–	715
2017 Q2	$467K	Buy	+5,858	New	+$374K	﹤0.01%	593
2016 Q4	–	Sell	-400	Closed	-$27K	–	900
2016 Q3	$27K	Hold	400	–	–	﹤0.01%	848
2016 Q2	$22K	Hold	400	–	–	﹤0.01%	855
2016 Q1	$25K	Buy	+400	New	+$26.6K	﹤0.01%	847

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NN Investment Partners Holdings's ALNY Position: Q1 2022 in Review

NN Investment Partners Holdings opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2022: 10,948 shares worth $1.79M. The stake represents 0.01% of the portfolio and ranks #552 among its holdings. This is a return to the name: NN Investment Partners Holdings previously reported a position in ALNY as recently as Q3 2021.

NN Investment Partners Holdings first reported a position in ALNY in Q1 2016 and has held it in 12 quarters since. The position peaked at $5.91M in Q3 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

NN Investment Partners Holdings held 10,948 shares of Alnylam Pharmaceuticals worth $1.79M as of Q1 2022.
Alnylam Pharmaceuticals was a new NN Investment Partners Holdings position in Q1 2022.
Alnylam Pharmaceuticals made up 0.01% of NN Investment Partners Holdings's portfolio in Q1 2022, its #552 holding.
NN Investment Partners Holdings first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 12 quarters since.
NN Investment Partners Holdings's Alnylam Pharmaceuticals position peaked at $5.91M in Q3 2021.
444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on NN Investment Partners Holdings's 13F filing for Q1 2022, filed 11 May 2022.